Child hospitalized after nearly drowning in Plantation pool, authorities say doctor performed CPR before crews arrived
Just before 6:45 p.m., officials received a call about a child who nearly drowned in a pool near 400 Fan Palm Way in the Hawks Landing gated community.
When Plantation Police officers arrived, they began to take over resuscitation efforts from a physician who was already on scene and performing CPR on the child, Plantation Fire Lt. Ashton Bright told CBS News Miami.
Plantation Fire rescue crews arrived shortly after and took over resuscitation efforts as they took her to Broward Health Medical Center, Bright continued.
According to Bright, paramedics were able to revive the child while en route to the hospital and resuscitated her. Plantation Police told CBS News Miami that the child is listed in critical but stable condition.
Bright also told CBS News Miami that while it's unclear who the physician was or why they were there, he was thankful for their presence and for taking the initiative to start CPR while waiting for the authorities.
"It was truly a group effort tonight in trying to give this child a fighting chance," Bright said. "So, we really appreciate everyone's efforts tonight."
Bright also said Sunday's incident serves as a reminder to ensure everyone about pool safety.
"We always say, 'Watch the water, watch the kids,'" he said. "It only takes a few seconds for a child to go under and it's just a very unfortunate situation when that happens."
"The most important thing is that if you see someone who needs resuscitation is to spring into action," Bright continued, adding that everyone should learn CPR.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
17 minutes ago
- CNN
New ‘Make America Healthy Again' report to be released in weeks
Americans will have to wait several weeks for the Trump administration's next steps in its agenda to 'Make America Healthy Again,' according to three people familiar with the matter. While President Donald Trump's MAHA Commission will submit its strategy to the White House on Tuesday — sticking to an executive-ordered deadline — scheduling issues stand in the way of its public release. The commission is 'on track' to deliver its report to the White House by August 12, White House spokesman Kush Desai said in a statement. 'The report will be unveiled to the public shortly thereafter as we coordinate the schedules of the President and the various cabinet members who are a part of the Commission.' Officials are aiming to launch their strategy by the end of this month, according to the three people familiar. The commission's first MAHA report, issued in May, laid out the case that ultraprocessed foods, pharmaceutical prescriptions and environmental toxins are driving a crisis of childhood chronic disease in America. Much of the reports' findings echoed longtime arguments of health secretary Robert F. Kennedy Jr., who leads the commission. The second installment is expected to propose strategies and reforms to tackle those issues. Actions can include, per the president's executive order, ending certain federal practices that 'exacerbate the health crisis' and 'adding powerful new solutions.' Public health experts, MAHA supporters and industry advocates alike have been anxiously awaiting the commission's recommendations, and how far they will go. There is lingering unease among farmers and agricultural groups after the first report flagged studies that suggest links between commonly used pesticides and various illnesses such as cancer and liver problems. Groups like the American Farm Bureau Federation called those 'unproven theories' and warned that calling use of common pesticides into question could jeopardize Americans' confidence in the food supply. Federal health and agricultural officials sought to reassure farmers in the ensuing weeks. This month, a high-ranking Enviornmental Protection Agency official told attendees at a sugar industry conference that agencies would 'respect' the current regulatory framework, as reported by DTN Progressive Farmer, an agriculture news and analysis company. Another potential battleground is the federal path forward on ultraprocessed foods. Kennedy has led a public campaign for major food brands to voluntarily remove artificial additives and dyes from popular products, but nutrition advocates have pushed for the administration to crack down with regulations. This month, a former leader of the US Food and Drug Administration challenged the agency to remove ultraprocessed foods from the market by essentially outlawing certain ingredients. But some have remained skeptical that federal MAHA leaders will take drastic action. 'We need policies to change big food and the food system, so it produces healthier foods,' Jim Krieger, executive director of Healthy Food America, said in a news briefing Monday. 'Will [the MAHA commission] move beyond PR efforts, voluntary agreements and handshakes — none of which have really worked to improve the food system in the past — and suggest regulatory action with real teeth?'
Yahoo
23 minutes ago
- Yahoo
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
Announced design of Embolden™ registrational clinical trial of NGN-401 gene therapy for Rett syndrome; trial initiation activities underway Completed dosing in Phase 1/2 NGN-401 trial, and remains on track to report updated clinical efficacy and safety data in the second half of 2025 Cash runway into early 2028 NEW YORK, August 11, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. "In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities," stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "We are pleased to be moving forward with Embolden, which was purposefully and rigorously designed to differentiate NGN-401 by evaluating participants as young as three years of age with a primary endpoint that incorporates measures that KOLs, caregivers and payors believe to be clinically meaningful. Our previously announced reallocation of capital provides us runway into early 2028, enabling us to focus our resources on advancement of this potential therapy for the patients and families who urgently need new treatment options." Dr. McMinn continued, "In leveraging the continual dialogue under the START program, the FDA encouraged the analysis of the Embolden primary endpoint to remain at 12 months as the basis for full approval, noting that a 6-month endpoint may not be considered clinically meaningful. In further maintaining the rigorous design of the Embolden trial, we are electing to dose the last planned participant from the Phase 1/2 trial as part of the registrational Embolden trial and add one more participant to complete the proposed sample size at 20 patients." Second Quarter 2025 and Recent Highlights, and Anticipated Milestones NGN-401 Gene Therapy for Treatment of Rett Syndrome Received written agreement from the U.S. Food and Drug Administration (FDA) on key elements of the Embolden registrational trial of NGN-401 and refined the sample size to propose 20 participants Initiated Embolden clinical trial activities to support the conversion of the Phase 1/2 trial to a registrational trial Completed enrollment in the Phase 1/2 trial, with the last 5 additional participants dosed in the first half of 2025 Remains on track to report updated clinical efficacy and safety data from the Phase 1/2 trial in the second half of 2025 Presented at scientific conferences the hemophagocytic lymphohistiocytosis (HLH) monitoring and treatment algorithm incorporated into the NGN-401 clinical trial, which has been acknowledged as valuable information by the Rett syndrome and gene therapy communities There has been no evidence of HLH/hyperinflammatory syndrome in any NGN-401 trial participant at the 1E15 vg dose level, as of the date of this press release Upcoming Events Stifel Biotech Summer Summit: Management will participate in a fireside chat at 12:00 p.m. ET on August 12 (not webcast) H.C. Wainwright Annual Global Investment Conference: Management will participate in a fireside chat at 2:30 p.m. ET on September 8 and participate in 1x1 meetings Second Quarter 2025 Financial Results Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028. Research & Development (R&D) Expenses: R&D expenses were $19.4 million for the three months June 30, 2025 compared to $15.7 million for the three months ended June 30, 2024. The increase in R&D expenses for the three months ended June 30, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount. General & Administrative (G&A) Expenses: G&A expenses were $6.7 million for the three months ended June 30, 2025 compared to $5.3 million for the three months ended June 30, 2024. The increase in G&A expenses for the three months ended June 30, 2025 was primarily driven by an increase in employee-related expenses due to an increase in stock-based compensation, headcount and other corporate expenses. Net Loss: Net loss was $22.0 million for the three months ended June 30, 2025 compared to $18.5 million for the three months ended June 30, 2024. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicable U.S. securities law. Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial, and the timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial, anticipated timing of additional updates for the Embolden registrational trial of NGN-401 for Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome, expected future interactions with or positions of the FDA; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "on track," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things: the expected timing of additional results from the NGN-401 clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome; the risk that the Company may not be able to report data on the predicted timeline; risks related to the Company's ability to obtain regulatory approval for, and ultimately commercialize, its product candidates, including NGN-401; risks related to timing of initiating the Embolden trial of NGN-401 for Rett syndrome; and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission ("SEC") on August 11, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication. - Financial Tables Follow - Neurogene Inc. Condensed Consolidated Balance Sheet Data (In thousands of U.S. dollars) June 30,2025 December 31,2024 Assets Cash and cash equivalents $ 58,813 $ 136,586 Short-term investments 215,706 175,819 Other current assets 4,467 3,518 Non-current assets 18,330 19,807 Total assets $ 297,316 $ 335,730 Liabilities Current liabilities 15,440 15,157 Non-current liabilities 8,621 10,198 Total liabilities 24,061 25,355 Stockholders' equity 273,255 310,375 Total liabilities and stockholders' equity $ 297,316 $ 335,730 Neurogene Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except share information) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Revenue under licensing agreements — 925 — 925 Operating expenses: Research and development expenses 19,366 15,744 37,131 29,285 General and administrative expenses 6,715 5,315 14,869 10,553 Total operating expenses 26,081 21,059 52,000 39,838 Loss from operations (26,081 ) (20,134 ) (52,000 ) (38,913 ) Other income, net 4,065 1,642 7,337 3,500 Net loss $ (22,016 ) $ (18,492 ) $ (44,663 ) $ (35,413 ) Per share information: Net loss per share, basic and diluted $ (1.05 ) $ (1.09 ) $ (2.12 ) $ (2.09 ) Weighted-average shares of common stock outstanding, basic and diluted 21,055,378 16,941,524 21,025,996 16,922,630 View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Texas woman sues Marine, claiming he spiked her drink with abortion pills
A Texas woman is suing a U.S. Marine, alleging he spiked her drink with nearly a dozen abortion pills, killing their unborn child, after she rebuffed his repeated requests to 'get rid of it,' according to a wrongful death lawsuit filed in federal court Monday. Liana Davis alleges Christopher Cooprider secretly dissolved at least 10 abortion pills into a cup of hot chocolate that he prepared for her April 5 and then left the house and stopped responding as she profusely bled, the suit says. Cooprider, 34, declined to comment Monday. The lawsuit, filed in the U.S. District Court for the Southern District of Texas, contains several purported text messages the pair exchanged for weeks, beginning Jan. 31, when Davis asked Cooprider for his input in case she is confirmed to be pregnant. Cooprider said he 'would like to get rid of it,' the texts show, saying the two were 'not in love' or together and that it would be 'messed up to bring a child into the world without both parents raising them.' When Cooprider reiterated his desire for Davis to 'get rid of it' after her pregnancy test came back positive days later, she asked him to use a different phrase. 'Every time you say 'get rid of it' it's like an electric shock,' she wrote, according to the lawsuit. 'I literally feel like I'm going down the steepest hill on a roller coaster when I read that.' The following text messages allegedly show Cooprider telling Davis, without her approval, that he would order abortion pills online. The pills were purchased from Aid Access, an online service that ships abortion pills to Americans from abroad, according to the lawsuit. Aid Access, and Dr. Rebecca Gomperts, a Dutch physician who runs it, are also listed as defendants in the lawsuit. They did not immediately return requests for comment. For the next several weeks, Cooprider was unable to convince Davis to get an abortion, and the text messages grew more contentious. On March 6, Cooprider called the baby a 'thing' and blamed Davis for her 'psycho mentality' that he said caused her ongoing divorce. The lawsuit says Cooprider also threatened to testify against Davis in her divorce proceeding and bid to have custody of her three children. At the end of March, Cooprider texted that he wanted to 'abort this monstrosity of a situation' and said he felt 'trapped' by the situation. But on April 2, Cooprider appeared to change his tone in text messages to Davis. He proposed making them 'some warm relaxing tea' in what they could call a 'trust building night,' according to screenshots shared in the lawsuit. Davis, who was eight weeks pregnant, accepted. When the two met up at Davis' Corpus Christi residence on the night of April 5, Cooprider handed her a cup of hot chocolate shortly before midnight, according to the lawsuit. Within 30 minutes of drinking it, the suit says, Davis began hemorrhaging and cramping. Davis knew she had to go to the emergency room, but she knew she could not leave her three children who were sleeping upstairs, the suit said. They came up with a plan for Cooprider to pick up Davis' mother, who lived nearby, so she could watch the children while Cooprider took Davis to the hospital. But once Cooprider left the house, he became unreachable, according to the lawsuit. 'I am gushing blood. Please hurry,' Davis texted him around 12:30 a.m. Davis's mother took an Uber ride to her daughter's house around 1 a.m. Around that time, Cooprider apologized and said he had to catch a flight the next day, the suit said. A neighbor drove Davis to the hospital, where her unborn baby, whom she had named Joy, did not survive. Back home, Davis said she found the opened box of abortion pills and a pill bottle, which she turned over to the Corpus Christi police, according to the lawsuit. The suit claims Cooprider mixed 10 misoprostol pills into the hot chocolate. The Corpus Christi Police Department said there are no active investigations involving Cooprider. The Marine Corps did not immediately respond to a request for comment. This article was originally published on Solve the daily Crossword
